An Open-label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa (NESP)
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Proportion of subjects whose baseline score on the subjective FCST correctly estimates the baseline MHST score
baseline
No
MD
Study Director
Amgen
United States: Food and Drug Administration
20000220
NCT00540696
September 2001
September 2003
Name | Location |
---|